What's next for SA's failed HIV vaccine trial?
Researchers of the failed HVTN 702 trial are now concentrating on answering the big question on why the HIV candidate vaccine failed to prevent new infections. As they continue monitoring participants, scientists will be collecting blood samples to study the immune responses that are occurring in a person that has been vaccinated. An independent data and monitoring safety board found that the vaccine tested in the large-scale South African trial also called Uhambo, was ineffective, prompting the announcement of the trial's premature ending, earlier this month. Talking to Channel Africa's Jane Rabothata about the way forward, one of the lead researchers Dr Linda-Gail Bekker began by explaining the un-blinding process, where each participant is now getting to know if they were given the actual vaccine or a placebo which is an inactive ingredient.